Early diagnostics for acute intoxication in the emergency department are about more than just identifying the cause of an overdose. They can enable timely intervention, reduce the risk of fatal outcomes, and open the door to substance use disorder treatment and recovery The post Racing the Clock: The Life-or-Death Power of Early Drugs-of-Abuse Diagnostics in…
Nema Health has cracked the code on PTSD and has an amazing study showing that their technique of intensive cognitive processing therapy is over 99% effective in flat out curing it in under a month. CEO psychiatrist Sofia Noori took me through what PTSD is, a full demo of how their solution works, and showed…
Solera Health has launched a behavioral health network that connects members to partners Calm Health and Lyra Health for digital mental health, coaching and therapy services. The post Solera Health Launches Behavioral Health Network with Calm and Lyra appeared first on MedCity News.
Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs appeared first on MedCity News.
That is the title of a fantastic editorial from Olivença et al. (2024). A lot of people when they look at pharmaceutical prices think they are ‘too high’ or ‘too low’. But the question is, too high or too low relative to what? What are our goals in pharmaceutical pricing. The editorial clearly articulates the…
June has seen a slew of executive hires, promotions, exits and layoffs across the healthcare sector. For example, CVS Health and HCA Healthcare welcomed new executives, and Ascension and Optum Health announced that their CEOs are departing. There were also layoffs at organizations including Providence, UCSF Health and Vanderbilt University Medical Center. The post Healthcare…
The FDA has approved UCB’s Kygevvi for treating children and adults with thymidine kinase 2 deficiency, an inherited mitochondrial disorder. It’s the drugmaker’s first ultra-rare disease product. The post UCB Drug Becomes First FDA-Approved Treatment for Ultra-Rare and Fatal Mitochondrial Disease appeared first on MedCity News.
VBC does not necessarily mean a reduction in all utilization. Rather, it means a rebalancing: fewer avoidable admissions, but possibly more use of home-based care, ambulatory services, and proactive outreach. The post The VBC Paradox: How Health Systems Can Balance Inpatient Revenue With Value-Based Care Goals appeared first on MedCity News.
Beth Israel’s Terrance Lee, M.D., M.P.H., and Boston Children’s Hospital’s Chase Parsons, D.O., share their experiences with their go-live processes
Structure Therapeutics’ aleniglipron, a once-daily oral GLP-1 drug, led to an average 16% weight loss measured at 44 weeks. Based on these results, the biotech is preparing for Phase 3 testing expected to begin in the second half of this year. The post Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2…